Last checked at 3 Jan 2020 16:14
REDX PHARMA PLC
("Redx" or "the Company" or "the Group")
Posting of Circular to Shareholders
Alderley Park, 03 January 2020 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis today confirms that, following its announcement of 31 December 2019, the Circular setting out details of the proposed Capitalisation and Waiver of Rule 9 of the Takeover Code and giving notice of a General Meeting to approve the Resolutions has today been posted to Shareholders. The Circular will shortly also be available on the Company's website: www.redxpharma.com.
The General Meeting will be held at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH at 11.00am on 21 January 2020.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer |
|
James Mead, Chief Financial Officer |
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
|
|
WG Partners LLP (Joint Broker and financial adviser) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
|
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/